Varian Medical Systems (NYSE:VAR) Issues FY20 Earnings Guidance

Share on StockTwits

Varian Medical Systems (NYSE:VAR) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided EPS guidance of $5.30-5.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.23. The company issued revenue guidance of $3.515-3.612 billion, compared to the consensus revenue estimate of $3.49 billion.Varian Medical Systems also updated its FY 2020 guidance to $5.30-5.45 EPS.

VAR stock traded down $6.03 during mid-day trading on Friday, reaching $120.30. 966,280 shares of the stock traded hands, compared to its average volume of 615,856. Varian Medical Systems has a one year low of $103.92 and a one year high of $142.50. The stock has a market capitalization of $11.50 billion, a PE ratio of 25.98, a PEG ratio of 2.92 and a beta of 0.87. The business has a 50-day moving average price of $114.84 and a two-hundred day moving average price of $124.25.

Varian Medical Systems (NYSE:VAR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $1.21 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.21. Varian Medical Systems had a net margin of 9.65% and a return on equity of 24.42%. The business had revenue of $878.90 million for the quarter, compared to analysts’ expectations of $858.47 million. During the same quarter in the previous year, the business posted $1.16 earnings per share. The business’s revenue was up 9.6% compared to the same quarter last year. As a group, equities analysts anticipate that Varian Medical Systems will post 5.41 earnings per share for the current year.

VAR has been the topic of a number of research analyst reports. BTIG Research upgraded shares of Varian Medical Systems from a neutral rating to a buy rating and set a $130.00 price target on the stock in a report on Monday, October 14th. TheStreet cut shares of Varian Medical Systems from a b rating to a c+ rating in a report on Monday, August 5th. Robert W. Baird set a $158.00 price target on shares of Varian Medical Systems and gave the stock a buy rating in a report on Friday, July 26th. Zacks Investment Research cut shares of Varian Medical Systems from a strong-buy rating to a hold rating and set a $139.00 price target on the stock. in a report on Saturday, July 27th. Finally, ValuEngine cut shares of Varian Medical Systems from a buy rating to a hold rating in a report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $145.11.

In related news, SVP John W. Kuo sold 465 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $116.30, for a total value of $54,079.50. Following the completion of the sale, the senior vice president now directly owns 35,411 shares of the company’s stock, valued at $4,118,299.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 1,395 shares of company stock valued at $158,388. 0.78% of the stock is owned by insiders.

Varian Medical Systems Company Profile

Varian Medical Systems, Inc designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through two segments, Oncology Systems and Proton Solutions. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy, as well as related quality assurance equipment.

Recommended Story: How To Calculate Debt-to-Equity Ratio

Earnings History and Estimates for Varian Medical Systems (NYSE:VAR)

Receive News & Ratings for Varian Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AstraZeneca  Stock Rating Reaffirmed by Shore Capital
AstraZeneca Stock Rating Reaffirmed by Shore Capital
Jefferies Financial Group Reiterates Buy Rating for Assura
Jefferies Financial Group Reiterates Buy Rating for Assura
Quidel  Downgraded by BidaskClub
Quidel Downgraded by BidaskClub
United States Lime & Minerals  Downgraded by BidaskClub to “Hold”
United States Lime & Minerals Downgraded by BidaskClub to “Hold”
Liberum Capital Reaffirms Buy Rating for Hollywood Bowl Group
Liberum Capital Reaffirms Buy Rating for Hollywood Bowl Group
JPMorgan Chase & Co. Reiterates Buy Rating for British American Tobacco Plc Ads
JPMorgan Chase & Co. Reiterates Buy Rating for British American Tobacco Plc Ads


© 2006-2019 Ticker Report